{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:07:16Z","timestamp":1764950836923,"version":"3.46.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"DOI":"10.7759\/cureus.98526","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:02:22Z","timestamp":1764950542000},"source":"Crossref","is-referenced-by-count":0,"title":["Intravesical Botulinum Toxin Type A for an Overactive Bladder: A Single-Center Audit"],"prefix":"10.7759","author":[{"given":"Philip","family":"Abolanle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Eylert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulette","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coral","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20870","article-title":"Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence","volume":"29","author":"Abrams P","year":"2010","unstructured":"Abrams P, Andersson KE, Birder L, et al.. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010, 29:213-40. 10.1002\/nau.20870","journal-title":"Neurourol Urodyn"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.109975","article-title":"The use of botulinum toxin for the treatment of overactive bladder syndrome","volume":"29","author":"Orasanu B","year":"2013","unstructured":"Orasanu B, Mahajan ST. The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol. 2013, 29:2-11. 10.4103\/0970-1591.109975","journal-title":"Indian J Urol"},{"key":"ref3","unstructured":"National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women. management. (2019). Accessed: November 9, 2025: https:\/\/www.nice.org.uk\/guidance\/ng123."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001637","article-title":"Update on overactive bladder therapeutic options","volume":"31","author":"Babin CP","year":"2024","unstructured":"Babin CP, Catalano NT, Yancey DM, et al.. Update on overactive bladder therapeutic options. Am J Ther. 2024, 31:e410-9. 10.1097\/MJT.0000000000001637","journal-title":"Am J Ther"},{"key":"ref5","article-title":"Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as \"Ueber einen neuen ana\u00ebroben Bacillus und seine Beziehungen zum Botulismus\" in Zeitschrift f\u00fcr Hygiene und Infektionskrankheiten 26: 1-56, 1897","volume":"1","author":"van Ermengem E","year":"1979","unstructured":"van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as \"Ueber einen neuen ana\u00ebroben Bacillus und seine Beziehungen zum Botulismus\" in Zeitschrift f\u00fcr Hygiene und Infektionskrankheiten 26: 1-56, 1897. Rev Infect Dis. 1979, 1:701-19.","journal-title":"Rev Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)31908-7","article-title":"Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction","volume":"212","author":"Simpson LL","year":"1980","unstructured":"Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 1980, 212:16-21.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200009010-00018","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch B","year":"2000","unstructured":"Schurch B, St\u00f6hrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000, 164:692-7. 10.1097\/00005392-200009010-00018","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.033","article-title":"An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders","volume":"65","author":"Mangera A","year":"2014","unstructured":"Mangera A, Apostolidis A, Andersson KE, et al.. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014, 65:981-90. 10.1016\/j.eururo.2013.10.033","journal-title":"Eur Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial","volume":"185","author":"Herschorn S","year":"2011","unstructured":"Herschorn S, Gajewski J, Ethans K, et al.. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011, 185:2229-35. 10.1016\/j.juro.2011.02.004","journal-title":"J Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02171-3","article-title":"Efficiency and safety of noninvasive and intravesical therapy for adult neurogenic lower urinary tract dysfunction: a systematic review and network meta-analysis of randomized controlled trials","volume":"85","author":"Wang Q","year":"2025","unstructured":"Wang Q, Li C, Long Y, et al.. Efficiency and safety of noninvasive and intravesical therapy for adult neurogenic lower urinary tract dysfunction: a systematic review and network meta-analysis of randomized controlled trials. Drugs. 2025, 85:677-93. 10.1007\/s40265-025-02171-3","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12360","article-title":"Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure","volume":"68","author":"Karsenty G","year":"2014","unstructured":"Karsenty G, Baverstock R, Carlson K, et al.. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract. 2014, 68:731-42. 10.1111\/ijcp.12360","journal-title":"Int J Clin Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1089\/end.2005.19.880","article-title":"Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection","volume":"19","author":"Smith CP","year":"2005","unstructured":"Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol. 2005, 19:880-2. 10.1089\/end.2005.19.880","journal-title":"J Endourol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/toxins16080332","article-title":"Efficacy, satisfaction, and compliance: insights from 15 years of botulinum toxin use for female urgency urinary incontinence","volume":"16","author":"Manso M","year":"2024","unstructured":"Manso M, Soares JD, Henriques M, Botelho F, Silva C, Cruz F. Efficacy, satisfaction, and compliance: insights from 15 years of botulinum toxin use for female urgency urinary incontinence. Toxins (Basel). 2024, 16:332. 10.3390\/toxins16080332","journal-title":"Toxins (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13092147","article-title":"Urodynamic predictive factors for successful treatment outcomes following intravesical botulinum toxin a injection in patients with detrusor overactivity","volume":"13","author":"Lee YK","year":"2025","unstructured":"Lee YK, Kuo HC. Urodynamic predictive factors for successful treatment outcomes following intravesical botulinum toxin a injection in patients with detrusor overactivity. Biomedicines. 2025, 13:2147. 10.3390\/biomedicines13092147","journal-title":"Biomedicines"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25230","article-title":"Predictors for adverse events following intravesical botulinum toxin injections in men","volume":"42","author":"Ribeiro L","year":"2023","unstructured":"Ribeiro L, Leung LY, Tan N, et al.. Predictors for adverse events following intravesical botulinum toxin injections in men. Neurourol Urodyn. 2023, 42:1499-505. 10.1002\/nau.25230","journal-title":"Neurourol Urodyn"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-023-05685-0","article-title":"Injection site number and outcomes of intradetrusor onabotulinumtoxinA for refractory overactive bladder syndrome: a randomized clinical trial","volume":"35","author":"Zdroik A","year":"2024","unstructured":"Zdroik A, El Haraki A, Smith W, Badlani G, Parker-Autry C, Matthews C. Injection site number and outcomes of intradetrusor onabotulinumtoxinA for refractory overactive bladder syndrome: a randomized clinical trial. Int Urogynecol J. 2024, 35:119-26. 10.1007\/s00192-023-05685-0","journal-title":"Int Urogynecol J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-015-0737-2","article-title":"OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales","volume":"17","author":"Freemantle N","year":"2016","unstructured":"Freemantle N, Khalaf K, Loveman C, Stanisic S, Gultyaev D, Lister J, Drake M. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales. Eur J Health Econ. 2016, 17:911-21. 10.1007\/s10198-015-0737-2","journal-title":"Eur J Health Econ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1199430","article-title":"Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe","volume":"19","author":"Ruff L","year":"2016","unstructured":"Ruff L, Bagshaw E, Aracil J, Velard ME, Pardhanani G, Hepp Z. Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe. J Med Econ. 2016, 19:1107-15. 10.1080\/13696998.2016.1199430","journal-title":"J Med Econ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000000277","article-title":"Cost-effectiveness analysis of anticholinergics versus botox for urgency urinary incontinence: results from the anticholinergic versus botox comparison randomized trial","volume":"22","author":"Visco AG","year":"2016","unstructured":"Visco AG, Zyczynski H, Brubaker L, et al.. Cost-effectiveness analysis of anticholinergics versus botox for urgency urinary incontinence: results from the anticholinergic versus botox comparison randomized trial. Female Pelvic Med Reconstr Surg. 2016, 22:311-6. 10.1097\/SPV.0000000000000277","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5603\/GP.a2022.0105","article-title":"Quality of life in patients with overactive bladder following botulinum toxin treatment: a preliminary report","volume":"94","author":"Licow A","year":"2023","unstructured":"Licow A, Ciecwiez S, Brodowska A. Quality of life in patients with overactive bladder following botulinum toxin treatment: a preliminary report. Ginekol Pol. 2023, 94:593-8. 10.5603\/GP.a2022.0105","journal-title":"Ginekol Pol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/nau.70017","article-title":"Variation in the definitions of urinary retention in studies of intravesical botulinum toxin for idiopathic overactive bladder: a narrative systematic review","volume":"44","author":"Stavrou S","year":"2025","unstructured":"Stavrou S, Paynter JA, Carins T, Qin KR, Brennan J. Variation in the definitions of urinary retention in studies of intravesical botulinum toxin for idiopathic overactive bladder: a narrative systematic review. Neurourol Urodyn. 2025, 44:860-77. 10.1002\/nau.70017","journal-title":"Neurourol Urodyn"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/nau.70039","article-title":"Intravesical botulinum toxin injection for treating detrusor overactivity and poor compliance in posterior urethral valves-a preliminary experience","volume":"44","author":"Mohan Kunnath S","year":"2025","unstructured":"Mohan Kunnath S, Solomon E, Mishra P, Wright AJ, Clothier J, Garriboli M. Intravesical botulinum toxin injection for treating detrusor overactivity and poor compliance in posterior urethral valves-a preliminary experience. Neurourol Urodyn. 2025, 44:760-7. 10.1002\/nau.70039","journal-title":"Neurourol Urodyn"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5152\/tud.2020.19259","article-title":"Refractory bladder dysfunction: a multi-institutional experience with intravesical botulinum toxin-a injection in adult patients who underwent previous augmentation cystoplasty","volume":"46","author":"Martinez L","year":"2020","unstructured":"Martinez L, Tubre R, Roberts R, Boone T, Griebling TL, Padmanabhan P, Khavari R. Refractory bladder dysfunction: a multi-institutional experience with intravesical botulinum toxin-a injection in adult patients who underwent previous augmentation cystoplasty. Turk J Urol. 2020, 46:309-13. 10.5152\/tud.2020.19259","journal-title":"Turk J Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/442236-intravesical-botulinum-toxin-type-a-for-an-overactive-bladder-a-single-center-audit","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:02:27Z","timestamp":1764950547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/442236-intravesical-botulinum-toxin-type-a-for-an-overactive-bladder-a-single-center-audit"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.98526","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}